Michael Maitland
0000-0002-2476-5732
Intellia Therapeutics Inc
5 papers found
Refreshing results…
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets
Missing publications? Search for publications with a matching author name.